Argenx Se (ARGX) Profit After Tax (2016 - 2026)
Argenx Se (ARGX) posted quarterly Profit After Tax of $362.0 million for Q2 2026, up 101.22% year-on-year from $179.9 million in Q2 2025, and down 27.31% on a QoQ basis from $498.0 million in Q1 2026.
Argenx Se (ARGX) Profit After Tax (2016 - 2026) Analysis & Trends
Argenx Se (ARGX) has reported Profit After Tax for 11 consecutive years, with $362.0 million the latest figure, recorded in Q2 2026.
- Quarterly Profit After Tax rose 101.22% year-over-year to $362.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.6 billion (up 1740.86% YoY) and the FY2025 annual result came in at $1.3 billion, up 55.1% from the prior year.
- Profit After Tax fell to $362.0 million in Q2 2026 per ARGX's latest filing, from $498.0 million in the prior quarter.
- Over the last five years, Profit After Tax for ARGX reached as high as $498.0 million in Q1 2026 and fell as low as -$651.9 million in Q2 2022.
- A 5-year average of $67.9 million and a median of $80.7 million in 2023 frame the typical range for Profit After Tax.
- The largest YoY upside for Profit After Tax was 434.22% in 2022 against a maximum downside of 2967.68% in 2022.
- Year by year, Profit After Tax stood at $41.2 million in 2022, then slumped by 156.22% to -$23.2 million in 2023, then slumped by 2504.39% to -$603.8 million in 2024, then soared by 166.79% to $403.3 million in 2025, then dropped by 10.24% to $362.0 million in 2026.
- According to Business Quant data, Profit After Tax over the past three periods registered $362.0 million, $498.0 million, and $403.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -36.84 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -65.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Alnylam Pharmaceuticals | 35.71 Bn | 32.70 Bn | 959.66 Mn | 205.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 362.00 Mn |
| Mar 31, 2026 | 498.00 Mn |
| Dec 31, 2025 | 403.29 Mn |
| Sep 30, 2025 | 386.05 Mn |
| Jun 30, 2025 | 179.90 Mn |
| Mar 31, 2025 | 235.36 Mn |
| Dec 31, 2024 | -603.80 Mn |
| Sep 30, 2024 | 88.02 Mn |
| Jun 30, 2024 | -59.07 Mn |
| Mar 31, 2024 | -108.90 Mn |
| Dec 31, 2023 | -23.18 Mn |
| Sep 30, 2023 | -83.28 Mn |
| Jun 30, 2023 | 73.35 Mn |
| Mar 31, 2023 | 28.87 Mn |
| Dec 31, 2022 | 41.24 Mn |
| Sep 30, 2022 | 241.02 Mn |
| Jun 30, 2022 | -651.94 Mn |
| Mar 31, 2022 | 216.00 Mn |
| Dec 31, 2021 | 244.88 Mn |
| Sep 30, 2021 | -230.87 Mn |